PO-0914: Knowledge-based automated VMAT Planning for liver metastases  by Sharfo, A.W.M. et al.
S474                                                                                                                                         3rd ESTRO Forum 2015 
 
radiological changes on CT after treatment. Median patient 
age was 28 years (range 6–71). In addition to lung irradiation 
factors, clinical variables, along with left and right lung and 
heart dose-volume histogram parameters, were included in 
the analysis. We applied a random forest (RF) algorithm to 
assess the prediction power and to measure the importance 
of the variables.  We split the cohort into two groups with 
one group (toxicity group) having lung toxicity and the other 
group (case group) without toxicity. To make balanced data, 
we randomly selected 18 samples from the case group and 
combined them with 18 samples in the toxicity group, 
resulting in 36 patients in total. With the 36 patients, we 
performed a two-stage of RF. In the first RF, all predictors 
were used, selecting 1/3 of predictors at node split. Based on 
the out-of-bag (OOB) samples, we calculated the importance 
of each variable and removed 1/3 insignificant variables for 
further analysis. Then, using the remaining predictors, the 
second RF was performed, still choosing 1/3 of predictors at 
each node split from the remaining predictors. This 
procedure was iterated 50 times. Model performance was 
assessed using the area under the receiver operating 
characteristic curve (AUC). 
Results: In the first RF, AUC=0.62 was obtained on average. 
In the second RF, a slightly better performance was obtained 
with AUC=0.64 on average. RF variable importance scores for 
the top 20 predictors relevant to CT changes obtained in the 
first RF are presented in figure 1. It was observed that both 
lung and heart-related predictors were highly ranked, 
suggesting that there is a correlation between doses received 
in heart and CT changes in lung. 
Figure 1 
 
 
Conclusions: Applying RF method, we showed the importance 
of jointly considering lung and heart irradiation in the 
prediction of subclinical radiation-induced lung fibrosis. 
Although asymptomatic, lung fibrosis could result in future 
respiratory insufficiency and its prediction is important for 
long-term quality of life for HL survivors.  
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Purpose/Objective: To investigate whether computer-
optimized fully automated VMAT planning may improve 
treatment plans for patients with liver metastases. 
Materials and Methods: Nine patients with liver metastases, 
previously treated in our clinic at a Cyberknife (CK) to 60 Gy 
prescribed at the 80% isodose, were included in this study. 
For each study patient, using our in-house developed multi-
criterial optimizer for fully automated plan generation, an 
optimized plan with 29 equidistant coplanar beams was 
generated. Our optimizer uses the 2-phase ε-constraint 
(2pεc) lexicographic optimization algorithm, based on a fixed 
list of hard constraints and prioritized objectives. This so-
called 'wish-list' is generated in an iterative procedure based 
on physicians' evaluation of initial plans generated for the 
first few patients. First priority was to achieve the highest 
possible coverage of the planning target volume (PTV) by the 
prescription dose, while not violating the clinically applied 
hard constraints. After optimization, a template containing 
the achieved results for the objectives and constraints is 
automatically generated, and fed into the clinical TPS 
(Monaco 5.0) to generate a clinically deliverable dual-arc 
VMAT plan without requiring any human interference. This 
plan was compared to the manually generated CK plan, 
comprising multiple non-coplanar beams, with respect to PTV 
dose coverage, mean dose and near-maximum dose (D2%) in 
the OARs. 
Results: In the automatically generated VMAT plans, PTV 
coverage increased by 0.8% on average (p = 0.594). All VMAT 
plans complied with the clinical constraints. This also applied 
to the patients in which the maximum dose in the spinal cord 
was slightly, but not significantly higher than in the CK plans 
(p = 0.314). For most of the other OARs large reductions in 
mean and near-maximum doses were observed (see Figure). 
The volumes of healthy liver receiving 15 Gy, 18 Gy and 21.6 
Gy (clinical constraints) were reduced by 1%, 3.7% and 1.6%, 
respectively. In addition the mean dose in the healthy liver 
was significantly reduced by 2.5±0.8 Gy (p = 0.008). The 
near-maximum dose in the bowel, duodenum, esophagus, 
heart, right kidney and gallbladder was significantly lower (p 
< 0.05), with population mean reductions of 20.7%, 22.5%, 
11.9%, 27.4%, 18.8% and 20.6%, respectively. Estimated 
delivery times for VMAT were a factor of eight shorter 
compared to CK plans (5.3±1.3 minutes versus 42±12 
minutes). 
 
 
Figure: Difference in OARs near-maximum and mean doses for 
automatically generated VMAT plans compared to CK plans. 
The dots give the population mean values for the 9 study 
patients and the error bars indicate ± 1 standard deviation. 
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Negative values are in favor of VMAT plans. *: difference is 
statistically significant (p<0.05). 
Conclusions: For the liver patients, the automatically 
generated dual-arc VMAT plans are substantially better than 
the manually generated non-coplanar CK plans, while 
requiring no workload. In addition, delivery times with VMAT 
are much shorter. 
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Purpose/Objective: A prospective observational study 
started in 2010 with the goal of developing predictive models 
of urinary (UR) toxicity (tox) and of erectile dysfunction after 
high dose radical radiotherapy (RT) for prostate cancer. Aim 
of this ad-interim analysis was to assess correlations between 
incidence of UR symptoms (symps) in the first 18 months 
(mos) after RT completion (as measured by the International 
Prostate Symptom Score, IPSS) and clinical/dosimetric risk 
factors.  
Materials and Methods: The trial included patients (pts) 
treated with conventional fractionation (74-80Gy at 1.8-
2Gy/fr) or moderate hypofractionation (65-75.2Gy at 2.2-
2.7Gy/fr), 5 fr/week. Prospectively collected clinical factors: 
T stage, comorbidities, drugs, androgen deprivation (AD), 
previous surgeries, smoking, alcohol, age, BMI. Bladder DVHs 
were corrected with alfa/beta=3Gy. IPSS was prospectively 
filled in at start/end of RT, at 3 and 6 mos follow-up (fup) 
and every 6 mos thereafter, till 5 yrs fup. We here 
considered an IPSS≥15 in the first 18 mos after RT completion 
as the UR tox endpoint (onset of moderate-severe UR symp), 
end RT IPSS was excluded, as relating to tox during RT. 
Analysis was accomplished for whole population and for 
subgroup with basal IPSS<15. A multivariate logistic 
regression (MVR) was performed. Choice of relevant factors 
to be included was carried out through an in-silico 
methodology combining bootstrap resampling, backward 
feature selection based on minimization of residuals and 
basket/network analysis of bootstrapped models. The 
features with the greatest % of occurrences (OCC) in the 
bootstrapped models were included in MVR. KNIME software 
was used. 
Results: By Nov 2014, 542 pts were enrolled. 
Clinical/dosimetric/endpoint data (18mos) available for 211 
pts, minimum fup 18mos. Incidence of IPSS≥15: 44/211 (21%) 
in the whole population and 34/193 (18%) in pts with basal 
IPSS<15. A 4-variable model was considered (AUC=0.81, CI 
0.75-0.86) including: basal IPSS (continuous variable, OR=1.2, 
OCC=98%), bladder volume receiving >78Gy (V78Gy, cont var, 
OR=1.09, OCC=69%), age (cont var, OR=1.05, OCC=34%) and 
diabetes (OR=2.7, OCC=20%). The model was confirmed for 
pts with basal IPSS<15 (AUC=0.79). 
Figure panel (a) shows %OCC of risk factors in 500 
simulations, while panel (b) reports rates of IPSS≥15 as a 
function of V78Gy. Minimizing V78Gy has a relevant impact 
on lowering toxicity incidence. ROC analysis suggests a cutoff 
V78Gy=6% (15% vs 34% UR tox below/above cutoff) 
 
Conclusions: Ad interim analysis shows an important 
correlation between UR tox at 18mos fup and bladder V78Gy, 
a cutoff V78Gy=6% can be suggested. Basal IPSS, age and 
diabetes act as modifiers of dose-response relationship (risk 
factors). Due to the timing of onset of late radioinduced UR 
toxicity (incidence increasing till 5yr fup), this interesting 
result has to be confirmed when longer fup will be available.  
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